Search

Displaying results 2721 - 2730 of 10000 in total
  1. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% E
  2. Drug

    Sodium phosphate, dibasic, unspecified form

    go.drugbank.com/drugs/DB14504
    Approved

    Mixtures: Aminosyn II in Dextrose
  3. Drug

    Dezocine

    go.drugbank.com/drugs/DB01209
    ApprovedInvestigational

    Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea.

  4. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.

  5. Drug

    Lesinurad

    go.drugbank.com/drugs/DB11560
    ApprovedWithdrawn

    Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target … In August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with

  6. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.

    Products: LOVENOX 10.000 IE (100 mg)/1 ml Injektionslösung in einer Fertigspritze, LOVENOX 15.000 IE (150 mg)/1 ml Injektionslösung in einer Fertigspritze
  7. Drug

    Myrrh

    go.drugbank.com/drugs/DB11605
    ApprovedInvestigational

    Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.

  8. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Patients experience an overdose may present with headache, tinnitus, numbness and tingling around the mouth and tongue, convulsions, inability to breathe, and decreased heart function.

  9. Drug

    Asfotase alfa

    go.drugbank.com/drugs/DB09105
    ApprovedInvestigational

    Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved … Food and Drug Administration (FDA) on October 23, 2015. Asfotase Alfa is marketed under the brand name Strensiq® by Alexion Pharmaceuticals, Inc.

  10. Drug

    Valrubicin

    go.drugbank.com/drugs/DB00385
    Approved

    It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder. … Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR.